Table 7.

Summary of dichotomous outcomes for vardenafil

		Number of		Percent with
Outcome	Dose (mg)	Trials	Patients	Vardenafil	Placebo	Relative benefit or risk (95% CI)	NNT/NNTp/NNH(95%CI)
Efficacy
Improved erections	5	3	833	62	27	2.3 (1.9 to 2.7)	2.9 (2.4 to 3.5)
	10	5	1401	68	21	3.3 (2.9 to 3.9)	2.1 (1.9 to 2.3)
	20	7	2147	73	22	3.4 (3.0 to 3.8)	2.0 (1.8 to 2.1)
	10/20	7	2856	71	22	3.3 (3.0 to 3.8)	2.0 (1.9 to 2.2)
Withdrawal
All-cause	10	3	812	4.2	2.5	1.7 (0.8 to 3.7)	not calculated
	20	5	1623	18	32	0.6 (0.5 to 0.7)	6.9 (5.4 to 9.7)
	10/20	5	2061	20	32	0.6 (0.5 to 0.6)	7.7 (6.0 to 11)
Lack of efficacy	5	2	505	11	18	0.6 (0.4 to 0.9)	14 (7.5 to 85)
	10	4	1084	4	15	0.3 (0.2 to 0.4)	9.3 (7.1 to 14)
	20	6	1831	4	13	0.3 (0.2 to 0.4)	11 (8.7 to 15)
	10/20	6	2320	4	12	0.3 (0.2 to 0.4)	11 (9.0 to 16)
Adverse event	5	3	812	4.2	2.5	1.7 (0.8 to 3.7)	not calculated
	10	5	1395	2.8	1.9	1.5 (0.7 to 3.0)	not calculated
	20	7	2161	3.6	1.8	2.1 (1.2 to 5.3)	54 (31 to 210)
	10/20	7	2868	3.3	1.8	1.8 (1.1 to 3.0)	65 (37 to 250)
Adverse events
All cause	10/20				insufficient data
Severe	10/20	3	1096	2.7	2.2	1.2 (0.5 to 2.8)	not calculated
Serious	10/20	5	1984	2.2	3.2	0.7 (0.4 to 1.2)	not calculated
Headache	10/20	6	2411	15	4.1	3.4 (2.4 to 4.8)	9.6 (7.9 to 12)
Dyspepsia	10/20	5	1972	3.8	0.3	7.3 (2.4 to 22)	31 (22 to 48)
Flushing	10/20	5	1984	13	0.8	13 (6.3 to 27)	8.0 (6.9 to 9.6)
Rhinitis	10/20	5	2212	7.9	3.6	2.2 (1.5 to 3.4)	23 (16 to 42)

NNT is given in standard font, NNTp in bold, and NNH in bold italic. No NNT/NNTp/NNH was calculated unless there was a statistically significant difference